iBio (IBIO) awards 430,000 stock options to its Chief Medical Officer
Rhea-AI Filing Summary
iBio, Inc. reported that its Chief Medical Officer, Molly Carr, received a grant of stock options covering 430,000 shares of common stock. The options have an exercise price of $1.40 per share and expire on July 30, 2036, with all 430,000 options held directly after the grant.
The award was granted on July 31, 2026 as an inducement award outside the iBio, Inc. 2023 Omnibus Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The options vest 25% on the one-year anniversary of the grant date, with an additional 6.25% vesting every three months thereafter, contingent on Ms. Carr’s continued employment.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Carr Molly
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) F1, F2 | 430,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 430,000 shares (Direct)
Footnotes (2)
- F1. Stock option granted as an inducement award to the Reporting Person that was granted outside of the iBio, Inc. 2023 Omnibus Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4) on July 31, 2026 (the "Grant Date").
- F2. Vesting 25% on the one-year anniversary of the Grant Date, with an additional 6.25% vesting every three months thereafter, provided the Reporting Person remains employed by iBio, Inc. through each applicable vesting date.
Key Figures
Stock options granted: 430,000 shares
Exercise price: $1.40 per share
Options after transaction: 430,000 shares
+2 more
5 metrics
Stock options granted
430,000 shares
Grant to Chief Medical Officer on July 31, 2026
Exercise price
$1.40 per share
Exercise price for the 430,000 stock options
Options after transaction
430,000 shares
Total derivative securities held directly following the grant
Initial vesting portion
25%
Vests on the one-year anniversary of the July 31, 2026 grant date
Subsequent vesting tranche
6.25%
Additional portion vesting every three months after the first anniversary
Key Terms
Stock Option (right to buy), inducement award, Nasdaq Listing Rule 5635(c)(4), 2023 Omnibus Incentive Plan, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
inducement award financial
"Stock option granted as an inducement award to the Reporting Person"
An inducement award is a special cash or equity payment given to a new hire—often an executive or key employee—outside the company’s regular pay plans to persuade them to join. Think of it like a signing bonus that can align the new person’s goals with shareholders but also represents a cost and can reduce existing owners’ percentage of the company, so investors watch these awards for their impact on ownership and future performance.
Nasdaq Listing Rule 5635(c)(4) regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4) on July 31, 2026"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
2023 Omnibus Incentive Plan financial
"granted outside of the iBio, Inc. 2023 Omnibus Incentive Plan"
vesting financial
"Vesting 25% on the one-year anniversary of the Grant Date"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What transaction did iBio (IBIO) report for Chief Medical Officer Molly Carr?
iBio reported that Chief Medical Officer Molly Carr received a grant of 430,000 stock options. The options are exercisable for iBio common stock at $1.40 per share, expiring on July 30, 2036, and are held directly by her.
What are the key terms of Molly Carr’s 430,000 iBio (IBIO) stock options?
The grant covers 430,000 options to purchase iBio common stock at an exercise price of $1.40 per share. The options expire on July 30, 2036 and were granted as compensation, with no cash paid for the award itself.
How do the iBio (IBIO) stock options granted to Molly Carr vest over time?
The options vest 25% on the one-year anniversary of the July 31, 2026 grant date. An additional 6.25% vests every three months thereafter, provided Molly Carr remains employed by iBio through each applicable vesting date.
Were Molly Carr’s iBio (IBIO) options granted under the 2023 Omnibus Incentive Plan?
No. The 430,000 stock options were granted as an inducement award outside the iBio, Inc. 2023 Omnibus Incentive Plan. The grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) on July 31, 2026.
How many iBio (IBIO) derivative securities does Molly Carr hold after this Form 4 transaction?
Following the reported grant, Molly Carr holds 430,000 stock options related to iBio common stock. These options represent the full amount acquired in this transaction and are reported as directly owned derivative securities after the award.